Robert E. Waltermire
Senior VP, Chief Pharma Dev. at Madrigal Pharmaceuticals, Inc. (MDGL) since August 2021
Robert E. Waltermire has filed 16 insider reports with the SEC since August 2021, as senior VP and chief Pharma Dev. at Madrigal Pharmaceuticals, Inc. (MDGL). Robert E. Waltermire made no open-market purchases or sales in the last 12 months. In the latest filing, on March 7, 2025, Robert E. Waltermire sold 14,113 shares of Madrigal Pharmaceuticals, Inc. (MDGL) for $4.82M at an average of $341.32.
- Filings
- 16
- Companies
- 1
- Bought on market
- None
- Sold on market
- $11.3M
Companies where Robert E. Waltermire is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Senior VP, Chief Pharma Dev.since August 2021 | 5,789 | $11.3M | $421.99 | Mar 7, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Mar 5, 2025-$4.82MMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. exercised 14,113 shares at a strike of $87.49, sold $4,817,104 worth of shares (14,113 units at $341.32) and was granted 2,061 shares, increasing direct ownership by 55% to 5,789 unitsForm 4Grant or awardExercise or conversion of a derivativeOpen-market sale
- Feb 28, 2025-$418KMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. sold $418,488 worth of shares (1,227 units at $341.07), decreasing direct ownership by 25% to 3,728 unitsForm 4Open-market sale
- Jan 24, 2025-$34.5KMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. sold $34,530 worth of shares (103 units at $335.24), decreasing direct ownership by 2% to 4,955 unitsForm 4Open-market sale
- Jan 17, 2025-$121KMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. sold $120,847 worth of shares (442 units at $273.41), decreasing direct ownership by 8% to 5,058 unitsForm 4Open-market sale
- Jun 14, 2024-$532KMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. sold $532,000 worth of shares (1,900 units at $280.00) and exercised 1,900 shares at a strike of $87.09Form 4Exercise or conversion of a derivativeOpen-market sale
- Jun 12, 2024-$570KMDGLSenior VP, Chief Pharma Dev. Waltermire Robert E. exercised 2,000 shares at a strike of $87.92 and sold $570,000 worth of shares (2,000 units at $285.00)Form 4Exercise or conversion of a derivativeOpen-market sale
- May 21, 2024-$240KMDGLWaltermire Robert E. sold $239,668 worth of shares (1,036 units at $231.34), decreasing direct ownership by 16% to 5,500 unitsForm 4Open-market sale
- Jan 23, 2024MDGLWaltermire Robert E. was granted 1,419 shares, increasing direct ownership by 28% to 6,536 unitsForm 4Grant or award
- Jan 16, 2024MDGLWaltermire Robert E. covered exercise/tax liability with 550 shares, decreasing direct ownership by 10% to 5,117 unitsForm 4Shares withheld for taxes or exercise price
- Dec 15, 2023-$942KMDGLWaltermire Robert E. exercised 4,000 shares at a strike of $87.92 and sold $942,000 worth of shares (4,000 units at $235.50)Form 4Exercise or conversion of a derivativeOpen-market sale
- Dec 13, 2023-$847KMDGLWaltermire Robert E. exercised 3,800 shares at a strike of $87.92 and sold $846,700 worth of shares (3,800 units at $222.82)Form 4Exercise or conversion of a derivativeOpen-market sale
- Mar 1, 2023-$2.73MMDGLSEC Form 4: Waltermire Robert E. sold $2,732,438 worth of shares (10,000 units at $273.24) and exercised 10,000 shares at a strike of $87.92Form 4Exercise or conversion of a derivativeOpen-market sale
- Jan 16, 2023MDGLSEC Form 4: Waltermire Robert E. was granted 5,667 sharesForm 4Grant or award
- Feb 24, 2022MDGLSEC Form 4 filed by Waltermire Robert E.Form 4Grant or award
- Aug 2, 2021MDGLSEC Form 4 filed by Waltermire Robert E.Form 4Grant or award
- Aug 2, 2021MDGLSEC Form 3 filed by Waltermire Robert E.Form 3New insider
Compare Robert E. Waltermire with
- Robert E. Waltermire vs Shannon T Kelley1 shared
- Robert E. Waltermire vs William John Sibold1 shared
- Robert E. Waltermire vs John C Reed1 shared
- Robert E. Waltermire vs Rebecca Taub1 shared
- Robert E. Waltermire vs Richard S Levy1 shared
- Robert E. Waltermire vs Jacqualyn A Fouse1 shared
Other insiders at the same companies
- Baker Bros. Advisors LPMDGL
- Shannon T KelleyMDGL
- William John SiboldMDGL
- John C ReedMDGL
- Rebecca TaubMDGL
- Richard S LevyMDGL
- Jacqualyn A FouseMDGL
- James M DalyMDGL
- Daniel J. BrennanMDGL
- David SoergelMDGL
- Mardi DierMDGL
- Carole HuntsmanMDGL
- Rita ThakkarMDGL
- Paul A FriedmanMDGL
- Kenneth BateMDGL
- Fred B CravesMDGL
Questions about Robert E. Waltermire
- What is Robert E. Waltermire's role at Madrigal Pharmaceuticals, Inc.?
- Robert E. Waltermire reports to the SEC as senior VP and chief Pharma Dev. at Madrigal Pharmaceuticals, Inc. (MDGL), according to the latest filing on March 7, 2025.
- How many shares does Robert E. Waltermire own?
- After the latest filing that states it, Robert E. Waltermire directly owned 5,789 shares of Madrigal Pharmaceuticals, Inc. (MDGL). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Robert E. Waltermire bought or sold stock recently?
- The most recent open-market sale was on March 5, 2025: sold 14,113 shares of Madrigal Pharmaceuticals, Inc. (MDGL) for $4.82M at an average of $341.32.
- How do I get alerts when Robert E. Waltermire files?
- Follow Robert E. Waltermire on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Robert E. Waltermire (SEC CIK 0001876996). Totals count each trade once, skipping amendments whose original is on file, from Aug 5, 2021 on. View on SEC EDGAR